The first antiestrogen for ERα-positive breast cancer treatment was tamoxifen, a selective estrogen receptor modulator, inhibiting the activity of the estrogen receptor alpha (ERα)[5,6]. The gene discussed is ESR1; the disease is breast carcinoma.